{'fraction_non_alphanumeric': 0.04006968641114982, 'fraction_numerical': 0.028745644599303136, 'mean_word_length': 6.226415094339623, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria

The in vitro activities of daptomycin (LY146032), paldimycin (U-70,138F), vancomycin, and penicillin G against 344 clinical isolates of anaerobic gram-positive bacteria were determined by an agar dilution method in calcium-supplemented (50 micrograms/ml) Wilkins-Chalgren medium, using an inoculum of 10(5) CFU. Daptomycin demonstrated excellent activity against a broad range of anaerobic gram-positive cocci and bacilli, including Peptostreptococcus, Eubacterium, Bifidobacterium, Actinomyces, Propionibacterium, and Lactobacillus species and Clostridium difficile. Highly resistant strains (MIC, greater than or equal to 64 micrograms/ml) were encountered sporadically from different genera, but these accounted for only 3% of all isolates tested. Vancomycin showed similar activity but was less active against Lactobacillus species and Peptostreptococcus prevotii. Paldimycin was inactive against most genera of anaerobic gram-positive bacteria. Overall, penicillin G remained the most broadly active agent against these isolates.